Trends in Late Stage Licensing
Executive Summary
What type of pharmaceutical companies are the most aggressive licensors of late-stage products? In Vivo examines late-stage deals by type of licensor over the past three years to get an idea.
You may also be interested in...
In Context: Aventis-Genta after Bristol-ImClone
Bristol-Myers Squibb's licensing arrangement for ImClone's Erbitux--both its upfront cash value and its subsequent level of disappointment--continues to define the industry's late-stage dealmaking. Genta's development and marketing alliance with Aventis for Genta's phase III anti-cancer chemosensitizer, Genasense, is no exception: the deal is both bigger, and smaller, than it might once have been had BMS and ImClone not stirred up the dealmaking pot. The Genta product was one of the only remaining unpartnered, important late-stage cancer projects available from a biotech company. It commanded a hefty price --at $135 million in upfront and near-term assured cash terms, and another $345 million in milestones. Before ImClone, Aventis says, it could have gotten this deal for less money. But if the ImClone transaction hadn't gone suddenly south (the FDA in December refused to accept ImClone's BLA submission for Erbitux), Aventis might also have had to pay far more.
US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
Need a specific report? 1000+ reports available
Buy Reports